Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Trametinib in MSS Metastatic Colon Cancer
NCT03428126Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2018
- Primary completion
- May 2022
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, trametinib in metastatic colorectal cancer (mCRC), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2018; status: completed.
02
Drugs
durvalumabtrametinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03428126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03428126.